Boston Biomedical’s Investigational Cancer Stem Cell Pathway Inhibitor, Napabucasin (BBI608), Featured at the ASCO … – PR Newswire (press release)
|
Boston Biomedical's Investigational Cancer Stem Cell Pathway Inhibitor, Napabucasin (BBI608), Featured at the ASCO …
PR Newswire (press release) CAMBRIDGE, Mass., Jan. 25, 2016 /PRNewswire/ — Boston Biomedical, an industry leader in the development of novel compounds designed to target cancer stem cell (CSC) pathways, announced that three poster presentations were highlighted at the 2016 … |
